Biotech Values

[rfj1862]

Are U or anyone else here following the OMER and KDNY P 3 IgA Nephropathy trials with 2023 readouts ?
Currently 2 IgA drugs recently approved ...both very expensive , one with a boxed warning .
May write a post on them later

Not sure that either of these represent good investments. Novartis' oral proximal complement inhibitor will likely be the game changer in this space.